In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- David Kantaros, Partner, Foley & Lardner LLP
- Fouad Azzam, Ph.D., General Partner, Life Sciences Partners
- Jeff Barlow, Managing Director, Head of US Life Sciences Investment Banking, Canaccord Adams
- Stacy Coen, Senior Director of Business Development, Genzyme Corporation
- Robert Mashal, Ph.D., President & CEO, NKT Therapeutics Inc.
Related Insights
11 February 2025
Foley Ignite
Where is corporate venture capital headed in 2025, and will it lead to more M&A?
Corporate Venture Capital (CVC) investment is an increasingly used strategic tool that enables large corporations to make minority investments in startups that will complement and expand their existing products or services.
11 February 2025
Labor & Employment Law Perspectives
Illinois Takes Aim at Artificial Intelligence in Employment
In a significant move to regulate artificial intelligence (AI) in the workplace, the Illinois Legislature amended the Illinois Human Rights Act to address the growing use of AI at various points throughout the employment process.
18 February 2025
Events
Hellenic Innovation Network of New York: Innovation & Impact
Join Foley & Lardner LLP and the Hellenic Innovation Network in our New York office on February 18th for an evening of Innovation & Impact.